LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

InflaRx NV

Fechado

0.8

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.74

Máximo

0.82

Indicadores-chave

By Trading Economics

Rendimento

-3.2M

-8.3M

EPS

-0.13

Margem de lucro

1,208,456.738

Funcionários

74

EBITDA

-3.2M

-8.2M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+602.41% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-59M

54M

Abertura anterior

0.8

Fecho anterior

0.8

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

InflaRx NV Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de jun. de 2025, 20:51 UTC

Ganhos

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de jun. de 2025, 20:48 UTC

Conversa de Mercado

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 de jun. de 2025, 20:46 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 de jun. de 2025, 20:46 UTC

Conversa de Mercado

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 de jun. de 2025, 19:31 UTC

Conversa de Mercado

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 de jun. de 2025, 19:19 UTC

Conversa de Mercado

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 de jun. de 2025, 19:16 UTC

Conversa de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 de jun. de 2025, 18:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de jun. de 2025, 18:42 UTC

Conversa de Mercado

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 de jun. de 2025, 18:39 UTC

Conversa de Mercado
Ganhos

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 de jun. de 2025, 18:29 UTC

Conversa de Mercado

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 de jun. de 2025, 18:18 UTC

Conversa de Mercado

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 de jun. de 2025, 18:16 UTC

Conversa de Mercado

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 de jun. de 2025, 17:16 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 de jun. de 2025, 17:08 UTC

Ganhos

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 de jun. de 2025, 16:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 de jun. de 2025, 16:22 UTC

Ganhos

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

27 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

27 de jun. de 2025, 15:59 UTC

Conversa de Mercado

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 de jun. de 2025, 15:56 UTC

Conversa de Mercado

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparação entre Pares

Variação de preço

InflaRx NV Previsão

Preço-alvo

By TipRanks

602.41% parte superior

Previsão para 12 meses

Média 5.83 USD  602.41%

Máximo 10 USD

Mínimo 2 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para InflaRx NV - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

6

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.29 / 1.85Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Neutral Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.